SalioGen Therapeutics operates a genome engineering platform designed to offer safe, affordable, and long-lasting non-viral gene therapies to patients suffering from inherited diseases. The company's gene engineering technology, derived from mammals, can be utilized in potentially curative non-viral gene therapy. This allows the healthcare industry to enhance cell therapy, cell engineering, and biologics production for patients in need.

Investors Include:

GordonMD Global Investments, Partners Investment, Cystic Fibrosis Foundation, D1 Capital Partners, General Inception, Fidelity Management & Research, Retinal Degeneration Fund, EPIQ Capital Group, PBM Capital, SymBiosis Capital Management, T. Rowe Price Group.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund